Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Outlook Therapeutics, Inc.OTLK · Entity 608 | Director | October 01, 2025 | October 03, 2025 |
| Presbia PLCLENS · Entity 160670 | Director | December 17, 2018 | December 19, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Outlook Therapeutics, Inc.
Report date October 01, 2025 · Filed October 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.04 · Expires 2035-10-01 | Direct | 286,734 |
Reported balance
After 2025-10-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-10-01 · Grant · Acquired 286,734 · Balance 286,734 F1: This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the "2024 Plan") and shall fully vest on October 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.06 · Expires 2035-10-03 | Direct | 58,648 |
Reported balance
After 2025-10-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-10-03 · Grant · Acquired 58,648 · Balance 58,648 F2: The options were granted under the 2024 Plan in lieu of $55,000 cash fees payable under the Issuer's Non-Employee Director Compensation Policy and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control. |
Filing footnotes · ownership attribution and instrument terms
F1: This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the "2024 Plan") and shall fully vest on October 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.
F2: The options were granted under the 2024 Plan in lieu of $55,000 cash fees payable under the Issuer's Non-Employee Director Compensation Policy and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.
Presbia PLC
Report date December 17, 2018 · Filed December 19, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.53 · Expires 2025-09-17 | Direct | 81,743 |
Reported balance
After 2018-12-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-12-17 · Grant · Acquired 81,743 · Balance 81,743 F1: On December 17, 2018, the Reporting Person was granted 81,743 stock options, which vest on December 16, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 17, 2018, the Reporting Person was granted 81,743 stock options, which vest on December 16, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 03, 2025 Filed Oct 3, 2025 19:14 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 58,648 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001649989-25-000005 · primary_doc.xml · derivative · entry 2 Auffarth Gerd · CIK 0001649867 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,648 Underlying: Common Stock · 58,648 shares Expires 2035-10-03 F2 · derivative.exercise_date: The options were granted under the 2024 Plan in lieu of $55,000 cash fees payable under the Issuer's Non-Employee Director Compensation Policy and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 19:14 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 286,734 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001649989-25-000005 · primary_doc.xml · derivative · entry 1 Auffarth Gerd · CIK 0001649867 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 286,734 Underlying: Common Stock · 286,734 shares Expires 2035-10-01 F1 · derivative.exercise_date: This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the "2024 Plan") and shall fully vest on October 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control. Read SEC document |
| October 03, 2024 Filed Oct 3, 2024 20:30 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 12,082 | $0.00 Strike: $5.25 | $0.00 |
DisclosureSEC source: 0001415889-24-024706 · form4-10032024_081011.xml · derivative · entry 3 Auffarth Gerd · CIK 0001649867 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,082 Underlying: Common Stock · 12,082 shares Expires 2034-10-03 F3 · derivative.exercise_date: The options were granted under the 2024 Plan in lieu of $55,000 cash fees payable under the Issuer's Non-Employee Director Compensation Policy and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:30 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 29,493 | $0.00 Strike: $5.22 | $0.00 |
DisclosureSEC source: 0001415889-24-024706 · form4-10032024_081011.xml · derivative · entry 2 Auffarth Gerd · CIK 0001649867 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,493 Underlying: Common Stock · 29,493 shares Expires 2034-10-01 F2 · derivative.exercise_date: This option grant was made under the 2024 Plan and shall fully vest on October 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:30 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 56,636 | $0.00 Strike: $5.22 | $0.00 |
DisclosureSEC source: 0001415889-24-024706 · form4-10032024_081011.xml · derivative · entry 1 Auffarth Gerd · CIK 0001649867 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,636 Underlying: Common Stock · 56,636 shares Expires 2034-10-01 F1 · derivative.exercise_date: This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the "2024 Plan") and shall fully vest on October 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control. Read SEC document |
| March 07, 2024 Filed Mar 8, 2024 16:14 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 94,441 | $0.00 Strike: $0.41 | $0.00 |
DisclosureSEC source: 0001415889-24-007338 · form4-03082024_090337.xml · derivative · entry 1 Auffarth Gerd · CIK 0001649867 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,441 Underlying: Common Stock · 94,441 shares Expires 2034-03-07 F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall fully vest on the earlier of (i) March 7, 2025; or (ii) the date of the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control. Read SEC document |
| October 04, 2023 Filed Oct 5, 2023 17:13 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 210,225 | $0.00 Strike: $0.24 | $0.00 |
DisclosureSEC source: 0001209191-23-052238 · doc4.xml · derivative · entry 1 Auffarth Gerd · CIK 0001649867 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,225 Underlying: Common Stock · 210,225 shares Expires 2033-10-04 F1 · derivative.exercise_date: The options were granted under the 2015 Plan in lieu of $44,000 cash fees payable under the Issuer's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2024, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan. Read SEC document |
| March 29, 2023 Filed Mar 31, 2023 17:47 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 41,065 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001209191-23-021909 · doc4.xml · derivative · entry 1 Auffarth Gerd · CIK 0001649867 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,065 Underlying: Common Stock · 41,065 shares Expires 2033-03-29 F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall fully vest on the earlier of (i) March 29,2024; or (ii) the date of the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control. Read SEC document |
| October 05, 2022 Filed Oct 7, 2022 16:34 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 42,239 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0001209191-22-053116 · doc4.xml · derivative · entry 1 Auffarth Gerd · CIK 0001649867 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,239 Underlying: Common Stock · 42,239 shares Expires 2032-10-05 F1 · derivative.exercise_date: The options were granted under the 2015 Plan in lieu of $44,000 cash fees payable under the Issuer's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2023, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan. Read SEC document |
| March 23, 2022 Filed Mar 24, 2022 17:38 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 21,878 | $0.00 Strike: $1.92 | $0.00 |
DisclosureSEC source: 0001209191-22-020951 · doc4.xml · derivative · entry 1 Auffarth Gerd · CIK 0001649867 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,878 Underlying: Common Stock · 21,878 shares Expires 2032-03-23 F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall fully vest on the earlier of (i) March 23,2023; or (ii) the date of the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control. Read SEC document |
| October 05, 2021 Filed Oct 7, 2021 17:08 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 25,245 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001209191-21-059953 · doc4.xml · derivative · entry 1 Auffarth Gerd · CIK 0001649867 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,245 Underlying: Common Stock · 25,245 shares Expires 2031-10-05 F1 · derivative.exercise_date: The options were granted under the 2015 Plan in lieu of $44,000 cash fees payable under the Issuer's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2022, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan. Read SEC document |
| March 24, 2021 Filed Mar 26, 2021 18:09 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 20,873 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001209191-21-023286 · doc4.xml · derivative · entry 1 Auffarth Gerd · CIK 0001649867 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,873 Underlying: Common Stock · 20,873 shares Expires 2031-03-24 F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on March 24, 2022, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event. Read SEC document |
| October 05, 2020 Filed Oct 5, 2020 18:43 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 85,586 | $0.51 Strike: $0.71 | $43,999.76 |
DisclosureSEC source: 0001209191-20-053867 · doc4.xml · derivative · entry 1 Auffarth Gerd · CIK 0001649867 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,586 Underlying: Common Stock · 85,586 shares Expires 2030-10-05 F1 · derivative.exercise_date: The options were granted under the 2015 Plan in lieu of $44,000 cash fees payable under the Issuer's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan. Read SEC document |
| July 17, 2020 Filed Jul 21, 2020 18:04 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0001209191-20-043215 · doc4.xml · derivative · entry 1 Auffarth Gerd · CIK 0001649867 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2030-07-17 F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on July 17, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 18:51 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 19,874 | $0.99 Strike: $1.28 | $19,581.85 |
DisclosureSEC source: 0001209191-20-041199 · doc4.xml · derivative · entry 1 Auffarth Gerd · CIK 0001649867 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,874 Underlying: Common Stock · 19,874 shares Expires 2030-07-01 F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") in lieu of $19,582.42 cash fees payable under the Issuer's non-employee Director compensation program, and vest on the last day of the remaining fiscal quarter such that they are vested in full on September 30, 2020, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan. Read SEC document |
| April 20, 2020 Filed Apr 21, 2020 18:38 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001209191-20-025302 · doc4.xml · derivative · entry 1 Auffarth Gerd · CIK 0001649867 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-04-20 F1 · derivative.exercise_date: The option will vest in three equal annual installments such that the stock option will be fully vested as of the third anniversary of the grant date, subject to (x) the Reporting Person's Continuous Service to the Issuer through such vesting date and (y) acceleration upon a Change in Control. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 17:31 UTC | Presbia PLC LENS · Entity 160670 | GrantStock Option (right to buy) · Derivative | 81,743 | $0.00 Strike: $0.53 | $0.00 |
DisclosureSEC source: 0001209191-18-063545 · doc4.xml · derivative · entry 1 Auffarth Gerd · CIK 0001649867 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,743 Underlying: Ordinary Shares · 81,743 shares Expires 2025-09-17 F1 · derivative.exercise_date: On December 17, 2018, the Reporting Person was granted 81,743 stock options, which vest on December 16, 2019. Read SEC document |
| July 18, 2018 Filed Jul 20, 2018 16:19 UTC | Presbia PLC LENS · Entity 160670 | GrantStock Option (right to buy) · Derivative | 67,981 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0000905718-18-000674 · auffarth_fm4july182018.xml · derivative · entry 1 Auffarth Gerd · CIK 0001649867 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,981 Underlying: Ordinary Shares · 67,981 shares Expires 2025-04-18 Read SEC document |
| March 13, 2017 Filed Mar 22, 2017 17:11 UTC | Presbia PLC LENS · Entity 160670 | GrantOrdinary Shares | 12,738 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-17-000386 · auffarth_fm4mar132017.xml · nonDerivative · entry 1 Auffarth Gerd · CIK 0001649867 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,464 F1 · shares: On March 13, 2017, the Reporting Person was granted 12,738 restricted ordinary shares, which vest on March 13, 2018. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 16:47 UTC | Presbia PLC LENS · Entity 160670 | OtherSubscription Rights (right to buy) · Derivative | 19,269 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0000905718-17-000343 · auffarth_fm4mar102017.xml · derivative · entry 2 Auffarth Gerd · CIK 0001649867 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,460 shares Expires 2017-03-08 F2 · shares: Each subscription right entitled its holder to purchase 0.335297256 Ordinary Shares at a subscription price of $3.00 per whole Ordinary Share. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 16:47 UTC | Presbia PLC LENS · Entity 160670 | OtherOrdinary Shares | 6,460 | $3.00 | $19,380.00 |
DisclosureSEC source: 0000905718-17-000343 · auffarth_fm4mar102017.xml · nonDerivative · entry 1 Auffarth Gerd · CIK 0001649867 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,726 F1 · shares: On March 8, 2017, the Reporting Person delivered to the Issuer an irrevocable notice of exercise of his subscription rights to purchase 6,460 Ordinary Shares, together with payment of the requisite fee, pursuant to the rights offering set forth in the Prospectus filed pursuant to Rule 424(b)(4), filed with the SEC on January 27, 2017, as amended February 23, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.